Effect of sitagliptin on glycemic control and beta cell function in japanese patients given basal-supported oral therapy for type 2 diabetes

Endocrine Journal

Volumn 61, Issue 12, 2014, Pages 1213-1220

  Asai, Shiko ^a   Ohta, Akio ^a   Kato, Hiroyuki ^a   Sada, Yoshiyuki ^a   Nagai, Yoshio ^a   Kondo, Akihiko ^a   Sasaoka, Toshiyasu ^b   Tanaka, Yasushi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

BOT; DPP 4 inhibitor; Proinsulin C peptide ratio; Sitagliptin; Type 2 diabetes mellitus

Indexed keywords

1,5 ANHYDROSORBITOL; C PEPTIDE; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; METFORMIN; MIGLITOL; PIOGLITAZONE; PROINSULIN; SITAGLIPTIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FATTY ACID; GLARGINE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LONG ACTING INSULIN; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

AGED; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; DRUG EFFECT; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; JAPANESE (PEOPLE); MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE; ALGORITHM; ANTAGONISTS AND INHIBITORS; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; DRUG MONITORING; DRUG RESISTANCE; ETHNOLOGY; HYPERGLYCEMIA; JAPAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; SECRETION (PROCESS);

ADMINISTRATION, ORAL; AGED; ALGORITHMS; BIOLOGICAL MARKERS; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG MONITORING; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FATTY ACIDS, NONESTERIFIED; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; INSULIN-SECRETING CELLS; JAPAN; MALE; PROINSULIN; PYRAZINES; TRIAZOLES;

EID: 84919791757     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ14-0194     Document Type: Article

References (28)

1. Janka HU, Hessel F, Walzer S, Mã Ller E (2007) Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes—a simulation with the Diabetes Mellitus Model (DMM).Int J Clin Pharmacol Ther 45:623-630.
2. Pscherer S, Dietrich ES, Dippel FW, Neilson AR (2010) Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany.Int J Clin Pharmacol Ther 48:129-137.
3. Ohtani T, Ito T (2011) Safty and effectiveness of BOT(basal supported oral therapy) using insulin glargine in Japanese patients with type 2 diabetes-results from postmarketing surveillance of insulin glargine (ALOHA study).Shinyaku to Rinsho (J New Rem Clin) 60:458-475
4. Ohta A, Kato H, Murayama K, Hashimoto E, Murakami M, et al. (2014) Effect of insulin glargine on endogenous insulin secretion and beta-cell function in Japanese type 2 diabetic patients using oral antidiabetic drugs.Endocr J 61:13-18.
5. Amori RE, Lau J, Pittas AG (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298:194-206.
6. Neumiller JJ, Wood L, Campbell RK (2010) Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 30:463-484.
7. Takahara M, Shiraiwa T, Kaneto H, Katakami N, Matsuoka TA, et al. (2012) Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy. Endocr J 59:1131-1136.
8. Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, et al. (2010) Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.Diabetes Care 33: 1509-1515.
9. Takeda Y, Fujita Y, Honjo J, Yanagimachi T, Sakagami H, et al. (2012) Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia 55:404-412.
10. Mu J, Woods J, Zhou YP, Roy RS, Li Z, et al.(2006) Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55:1695-1704.
11. Pfützner A, Pfützner AH, Larbig M, Forst T (2004) Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Diabetes Technol Ther 6:405-412.
12. Pscherer S, Larbig M, von Stritsky B, Pfützner A, Forst T (2012) In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment.J Diabetes Sci Technol 6:634-640.
13. Pistrosch F, Köhler C, Schaper F, Landgraf W, Forst T, et al. (2013) Effects of insulin glargine versus metformin on glycemic variability, microvascular and betacell function in early type 2 diabetes.Acta Diabetol 50:587-595.
14. Iwamoto Y, Taniguchi T, Nonaka K, Okamoto T, Okuyama K, et al. (2010) Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase 4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 57:383-394.
15. Katsuno T, Ikeda H, Ida K, Miyagawa J, Namba M (2013) Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. Endocr J 60:733-742.
16. Muscelli E, Casolaro A, Gastaldelli A, Mari A, Seghieri G, et al. (2012) Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. JClin Endocrinol Metab 97:2818-2826.
17. Aaboe K, Knop FK, Vilsbøll T, Deacon CF, Holst JJ, et al. (2010) Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab 12:323-333.
18. Mari A, Scherbaum WA, Nilsson PM, Lalanne G, Schweizer A, et al. (2008) Characterization of the influence of vildagliptin on model-assessed β-cell function in patients with type 2 diabetes and mild hyperglycemia.J Clin Endocrinol Metab 93:103-109.
19. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, et al. (2010) Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 59:887-895.
20. Derosa G, Carbone A, Franzetti I, Querci F, Fogari E, et al. (2012) Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 98:51-60.
21. Bajaj M, Pratipanawatr T, Berria R, Pratipanawatr W, Kashyap S, et al. (2002) Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes.Diabetes 51:3043-3048.
22. Jovanovic A, Gerrard J, Taylor R (2009) The secondmeal phenomenon in type 2 diabetes. Diabetes Care 32:1199-1201.
23. Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, et al. (2009) One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients:a randomized, controlled trial. Diabetes Care 32:762-768.
24. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ,Couture P (2011) Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.Diabetes Obes Metab 13:366-373.
25. Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, et al. (1996) Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet 347: 1514-1518.
26. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, et al. (2008) Translating the A1C assay into estimated average glucose values.Diabetes Care 31:1473-1478.
27. Suwa T, Ohta A, Matsui T, Koganei R, Kato H, et al. (2010) Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM).Endocr J 57:135-140.
28. Aso Y, Ozeki N, Terasawa T, Naruse R, Hara K, et al. (2012)Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin